US regulator looks set to approve novel multidrug-resistant TB option

11 June 2019
2019_vials_lab_biotech_research_big

New York-headquartered charity TB Alliance has announced a positive decision from the US regulator’s scientific advisory body, in relation to an investigational multidrug-resistant (MDR) tuberculosis therapy.

Founded in South Africa, TB Alliance is a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB).

The group has been testing pretomanid in combination with bedaquiline and linezolid to treat adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive MDR TB.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology